FindMyRecallSubscribe
Class I: serious health riskTerminated

Fresenius Kabi Sodium Acetate Injection Recall

Sodium Acetate Injection, USP, 400 mEq / 100 mL (4 mEq / mL), packaged in 2 trays of 20…

Fresenius Kabi USA, LLC · Lake Zurich, IL

Risk level
Class I
Reported by FDA
Mar 30, 2022
Recall ID
D-0750-2022
Check your lot numberHow we source this data

Summary

Fresenius Kabi recalled Sodium Acetate Injection starting Mar 4, 2022. The FDA classified it as Class I (serious health risk) and published enforcement report D-0750-2022 on Mar 30, 2022. Reason: Presence of particulate matter: particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose. Status: Terminated.

Why it was recalled

Presence of particulate matter: particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.

Product description

Sodium Acetate Injection, USP, 400 mEq / 100 mL (4 mEq / mL), packaged in 2 trays of 20 vials per shipper (NDC 63323-032-00), each vial: 100 mL fill in a 100 mL vial (NDC 63323-032-04), Rx Only, Fresenius Kabi, Lake Zurich, IL 60047

Lot numbers, UPCs & expiration codes

Lot #: 6124193, 6124196, 6124226, Exp 05/2022; 6124532, Exp 06/2022; 6125333, Exp 12/2022; 6125678, Exp 01/2023; 6126846, Exp 08/2023

Where it was sold

Nationwide USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0750-2022
Classification
Class I
Status
Terminated
Recall initiated
Mar 4, 2022
FDA report date
Mar 30, 2022
Quantity
118,040 vials
Recall type
Voluntary: Firm initiated
Recalling firm
Fresenius Kabi USA, LLC

Original FDA data

Every field from FDA enforcement report D-0750-2022, exactly as published.

Show all FDA fields
City
Lake Zurich
State
IL
Status
Terminated
Country
United States
Event ID
89725
Address
3 Corporate Dr
Code information
Lot #: 6124193, 6124196, 6124226, Exp 05/2022; 6124532, Exp 06/2022; 6125333, Exp 12/2022; 6125678, Exp 01/2023; 6126846, Exp 08/2023
Postal code
60047-8930
Report date
Mar 30, 2022
Product type
Drugs
Recall number
D-0750-2022
Classification
Class I
Recalling firm
Fresenius Kabi USA, LLC
Product quantity
118,040 vials
Termination date
Sep 29, 2023
Reason for recall
Presence of particulate matter: particulates composed of carbon and oxygen with varying amounts of iron and trace amounts of sodium, silicon, chromium, aluminum and cellulose.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Sodium Acetate Injection, USP, 400 mEq / 100 mL (4 mEq / mL), packaged in 2 trays of 20 vials per shipper (NDC 63323-032-00), each vial: 100 mL fill in a 100 mL vial (NDC 63323-032-04), Rx Only, Fresenius Kabi, Lake Zurich, IL 60047
Distribution pattern
Nationwide USA
Recall initiation date
Mar 4, 2022
Initial firm notification
Letter
Center classification date
Apr 6, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0750-2022, published Mar 30, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls